Spotlight on atomoxetine in attention-deficit hyperactivity disorder in children and adolescents

CNS Drugs

Volumn 24, Issue 1, 2010, Pages 85-88

  Garnock Jones, Karly P ^a   Keating, Gillian M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Spotlights; Adolescents; Atomoxetine, general; Attention deficit hyperactivity disorder; Children; Norepinephrine reuptake inhibitors, general

Indexed keywords

ATOMOXETINE; DEXAMPHETAMINE; METHYLPHENIDATE; NORADRENALIN UPTAKE INHIBITOR; OROS; PSYCHOSTIMULANT AGENT; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; ADRENERGIC RECEPTOR AFFECTING AGENT; PROPYLAMINE;

ABDOMINAL PAIN; ADOLESCENT; ADOLESCENT DISEASE; ANXIETY DISORDER; ATTENTION DEFICIT DISORDER; CHILD; CHILDHOOD DISEASE; COMORBIDITY; COST EFFECTIVENESS ANALYSIS; DECREASED APPETITE; DRUG COST; DRUG EFFICACY; DRUG FORMULATION; DRUG INDICATION; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEADACHE; HUMAN; HYPERACTIVITY; INSOMNIA; LIVER TOXICITY; NAUSEA; NONHUMAN; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; REVIEW; RISK; SOMNOLENCE; SUBSTANCE ABUSE; SUICIDAL IDEATION; TIC; VOMITING; CLINICAL TRIAL; PATHOPHYSIOLOGY; PHARMACOECONOMICS;

ADOLESCENT; ADRENERGIC UPTAKE INHIBITORS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; CLINICAL TRIALS AS TOPIC; ECONOMICS, PHARMACEUTICAL; HUMANS; PROPYLAMINES;

EID: 77649244717     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.2165/11203670-000000000-00000     Document Type: Review

References (50)

1. Garnock-Jones KP, Keating GM. Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents. Pediatr Drugs 2009; 11 (3): 203-26
2. Barton J. Atomoxetine: a new pharmacotherapeutic approach in the management of attention deficit/hyperactivity disorder. Arch Dis Child 2005 Feb; 90 Suppl. 1: i26-9
3. Ledbetter M. Atomoxetine: a novel treatment for child and adult ADHD. Neuropsych Dis Treat 2006; 2 (4): 455-66 (Pubitemid 46321875)
4. Bolden-Watson C, Richelson E. Blockade of newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes. Life Sci 1993; 52 (12): 1023-9
5. Wong DT, Threlkeld PG, Best KL, et al. A new inhibitor of norepinephrine uptake devoid of affinity for receptors in rat brain. J Pharmacol Exp Ther 1982; 222 (1): 61-5 (Pubitemid 12096999)
6. Bymaster FP, Katner JS, Nelson DL, et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 2002 Nov; 27 (5): 699-711 (Pubitemid 35335888)
7. Cusack B, Nelson A, Richelson E. Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl) 1994; 114 (4): 559-65 (Pubitemid 24152135)
8. Zerbe RL, Rowe H, Enas GG, et al. Clinical pharmacology of tomoxetine, a potential antidepressant. J Pharmacol Exp Ther 1985; 232 (1): 139-43 (Pubitemid 15193663)
9. 3H]nisoxetine binding in rat brain. J Neurochem 1995; 64 (6): 2792-800
10. 3H]tomoxetine, an enantiomerically pure ligand for norepinephrine reuptake sites. Neurosci Lett 1993; 157 (2): 203-6
11. Wernicke JF, Faries D, Girod D, et al. Cardiovascular effects of atomoxetine in children, adolescents, and adults. Drug Saf 2003; 26 (10): 729-40 (Pubitemid 36976134)
12. Spencer TJ, Kratochvil CJ, Sangal RB, et al. Effects of atomoxetine on growth in children with attention-deficit/hyperactivity disorder following up to five years of treatment. J Child Adolesc Psychopharmacol 2007 Oct; 17 (5): 689-700
13. Heil SH, Holmes HW, Bickel WK, et al. Comparison of the subjective, physiological, and psychomotor effects of atomoxetine and methylphenidate in light drug users. Drug Alcohol Depend 2002 Jul 1; 67 (2): 149-56 (Pubitemid 34722402)
14. Lile JA, Stoops WW, Durell TM, et al. Discriminative-stimulus, self-reported, performance, and cardiovascular effects of atomoxetine in methylphenidate-trained humans. Exp Clin Psychopharmacol 2006 May; 14 (2): 136-47 (Pubitemid 43988631)
15. Sangal RB, Owens J, Allen AJ, et al. Effects of atomoxetine and methylphenidate on sleep in children with ADHD. Sleep 2006 Dec 1; 29 (12): 1573-85 (Pubitemid 44936466)
16. Witcher JW, Long A, Smith B, et al. Atomoxetine pharmacokinetics in children and adolescents with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 2003 Spring; 13 (1): 53-63 (Pubitemid 36570188)
17. Eli Lilly and Company. Atomoxetine (Strattera™) prescribing information [online]. Available from URL: http://pi.lilly.com/us/strattera-pi. pdf [Accessed 2009 Feb 9]
18. Belle DJ, Ernest CS, Sauer J-M, et al. Effect of potent CYP2D6 inhibition by paroxetine on atomoxetine pharmacokinetics. J Clin Pharmacol 2002 Nov; 42 (11): 1219-27 (Pubitemid 35205057)
19. Michelson D, Faries D, Wernicke J, et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics 2001 Nov; 108 (5): E83-91
20. Eli Lilly. Clinical study summary: study B4Z-MC-LYAC. A phase 3 randomized, double-blind, placebo-controlled efficacy and safety comparison of fixed-dose ranges (mg/kg/day) of tomoxetine with placebo in child and adolescent outpatients with ADHD, aged 8 to 18 years. [online]. Available from URL: http://www.clinicalstudyresults.org/documents/company-study-163-0.pdf [Accessed 2009 Feb 9]
21. Michelson D, Allen AJ, Busner J, et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry 2002 Nov; 159 (11): 1896-901 (Pubitemid 35283256)
22. Spencer T, Heiligenstein JH, Biederman J, et al. Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry 2002 Dec; 63 (12): 1140-7 (Pubitemid 36084059)
23. Gau SS, Huang YS, Soong WT, et al. A randomized, double-blind, placebo-controlled clinical trial on once-daily atomoxetine in Taiwanese children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2007 Aug; 17 (4): 447-60 (Pubitemid 47417773)
24. Brown RT, Perwien A, Faries DE, et al. Atomoxetine in the management of children with ADHD: effects on quality of life and school functioning. Clin Pediatr (Phila) 2006 Nov; 45 (9): 819-27 (Pubitemid 44570029)
25. Weiss M, Tannock R, Kratochvil C, et al. A randomized, placebo-controlled study of once-daily atomoxetine in the school setting in children with ADHD. J Am Acad Child Adolesc Psychiatry 2005 Jul; 44 (7): 647-55 (Pubitemid 40875359)
26. Kelsey DK, Sumner CR, Casat CD, et al. Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial. Pediatrics 2004 Jul; 114 (1): e1-8
27. Michelson D, Buitelaar JK, Danckaerts M, et al. Relapse prevention in pediatric patients with ADHD treated with atomoxetine: a randomized, double-blind, placebo-controlled study. J Am Acad Child Adolesc Psychiatry 2004 Jul; 43 (7): 896-904 (Pubitemid 38808495)
28. Buitelaar JK,Michelson D, Danckaerts M, et al. A randomized, double-blind study of continuation treatment for attention-deficit/hyperactivity disorder after 1 year. Biol Psychiatry 2007 Mar 1; 61 (5): 694-9 (Pubitemid 46328852)
29. Wernicke JF, Adler L, Spencer T, et al. Changes in symptoms and adverse events after discontinuation of atomoxetine in children and adults with attention deficit/hyperactivity disorder: a prospective, placebo-controlled assessment. J Clin Psychopharmacol 2004 Feb; 24 (1): 30-5 (Pubitemid 38134163)
30. Wilens TE, Kratochvil C, Newcorn JH, et al. Do children and adolescents with ADHD respond differently to atomoxetine? J Am Acad Child Adolesc Psychiatry 2006 Feb; 45 (2): 149-57
31. Escobar R, Montoya A, Polavieja P, et al. Evaluation of patients' and parents' quality of life in a randomized placebo-controlled atomoxetine study in attention-deficit/hyperactivty disorder. J Child Adolesc Psychopharmacol 2009; 19 (3): 253-63
32. Svanborg P, Thernlund G, Gustafsson PA, et al. Efficacy and safety of atomoxetine as add-on to psychoeducation in the treatment of attention deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled study in stimulant-naive Swedish children and adolescents. Eur Child Adolesc Psychiatry 2009 Apr; 18 (4): 240-9
33. Kratochvil CJ, Heiligenstein JH, Dittmann R, et al. Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial. J Am Acad Child Adolesc Psychiatry 2002 Jul; 41 (7): 776-84 (Pubitemid 38338092)
34. Wang Y, Zheng Y, Du Y, et al. Atomoxetine versus methylphenidate in paediatric outpatients with attention deficit hyperactivity disorder: a randomized, double-blind comparison trial. Aust NZ J Psychiatry 2007 Mar; 41 (3): 222-30 (Pubitemid 46705737)
35. Prasad S, Harpin V, Poole L, et al. A multi-centre, randomised, open-label study of atomoxetine compared with standard current therapy in UK children and adolescents with attention-deficit/hyperactivity disorder (ADHD). Curr Med Res Opin 2007 Feb; 23 (2): 379-94 (Pubitemid 46333386)
36. Kemner JE, Starr HL, Ciccone PE, et al. Outcomes of OROS® methylphenidate compared with atomoxetine in children with ADHD: a multicenter, randomized prospective study. Adv Ther 2005 Sep 31; 22 (5): 498-512 (Pubitemid 43130867)
37. Newcorn JH, Kratochvil CJ, Allen AJ, et al. Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response. Am J Psychiatry 2008; 165 (6): 721-30 (Pubitemid 351810541)
38. Wigal SB, McGough JJ, McCracken JT, et al. A laboratory school comparison of mixed amphetamine salts extended release (Adderall XR) and atomoxetine (Strattera) in school-aged children with attention deficit/hyperactivity disorder. J Atten Disord 2005 Aug; 9 (1): 275-89 (Pubitemid 41551759)
39. Bangs ME, Hazell P, Danckaerts M, et al. Atomoxetine for the treatment of attention-deficit/hyperactivity disorder and oppositional defiant disorder. Pediatrics 2008 Feb; 121 (2): e314-20
40. Bangs ME, Emslie GJ, Spencer TJ, et al. Efficacy and safety of atomoxetine in adolescents with attention-deficit/hyperactivity disorder and major depression. J Child Adolesc Psychopharmacol 2007 Aug; 17 (4): 407-20
41. Geller D, Donnelly C, Lopez F, et al. Atomoxetine treatment for pediatric patients with attention-deficit/hyperactivity disorder with comorbid anxiety disorder. J Am Acad Child Adolesc Psychiatry 2007 Sep; 46 (9): 1119-27 (Pubitemid 47295923)
42. Arnold LE, Aman MG, Cook AM, et al. Atomoxetine for hyperactivity in autism spectrum disorders: placebo-controlled crossover pilot trial. J Am Acad Child Adolesc Psychiatry 2006 Oct; 45 (10): 1196-205 (Pubitemid 44465640)
43. Allen AJ, Kurlan RM, Gilbert DL, et al. Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders. Neurology 2005 Dec 27; 65 (12): 1941-9 (Pubitemid 43970115)
44. Kratochvil CJ, Newcorn JH, Arnold LE, et al. Atomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety symptoms. J Am Acad Child Adolesc Psychiatry 2005 Sep; 44 (9): 915-24 (Pubitemid 41193203)
45. Bangs ME, Tauscher-Wisniewski S, Polzer J, et al. Meta-analysis of suicide-related behavior events in patients treated with atomoxetine. J Am Acad Child Adolesc Psychiatry 2008 Feb; 47 (2): 209-18 (Pubitemid 351158789)
46. Bangs ME, Jin L, Zhang S, et al. Hepatic events associated with atomoxetine treatment for attention-deficit hyperactivity disorder. Drug Saf 2008; 31 (4): 345-54 (Pubitemid 351441582)
47. Cottrell S, Tilden D, Robinson P, et al. A modeled economic evaluation comparing atomoxetine with stimulant therapy in the treatment of children with attention-deficit/hyperactivity disorder in the United Kingdom. Value Health 2008 May 30; 11 (3): 376-88 (Pubitemid 351712971)
48. Tilden D, Richardson R, Nyhus K, et al. A modelled economic evaluation of atomoxetine (Strattera) for the treatment of three patient groups with attention deficit hyperactivity disorder [abstract no. PMH5]. Value Health 2005 Dec 6; 8: A197. Plus poster presented at the International Society for Pharmacoeconomics and Outcomes Research Eighth Annual European Congress; 2005 Nov 6-8; Florence
49. Laing A, Cottrell S, Robinson P, et al. A modelled economic evaluation comparing atomoxetine with current therapies for the treatment of children with attention deficit/hyperactivity disorder in The Netherlands [abstract no. PMH10]. Value Health 2005 Dec 6; 8: A198. Plus poster presented at the International Society for Pharmacoeconomics and Outcomes Research Eighth Annual European Congress; 2005 Nov 6-8; Florence
50. Diamantopoulos A, Lorenzo M, Happich M, et al.A cost-utilty analysis of atomoxetine against current stimulant therapies for the treatment of children with attention deficit/hyperactivity disorder in Germany [abstract no. PMH36].Value Health 2007 Nov 31; 10: A298. Plus poster presented at the International Society for Pharmacoeconomics and Outcomes Research Tenth Annual European Congress; 2007 Oct 20-23; Dublin